Proteomic level changes associated with S3I201 treated U87 glioma cells

Area of Science:

• Proteomics
• Cancer Biology
• Molecular Oncology

Background:

• Glioblastoma multiforme (GBM) is a deadly brain tumor with limited treatment options.
• Signal Transducer and Activator of Transcription 3 (STAT3) is crucial for glioma progression and patient survival, making it a therapeutic target.
• S3I201 is a STAT3 inhibitor that reduces glioma tumor growth.

Purpose of the Study:

• To investigate the proteomic alterations in U87 glioma cells treated with S3I201.
• To identify downstream effects of STAT3 inhibition by S3I201.
• To explore the therapeutic potential of S3I201 in glioblastoma.

Main Methods:

• Utilized 2-DE and Isobaric tags for relative and absolute quantitation (iTRAQ) coupled with mass spectrometry for proteomic analysis.
• Performed functional classification of differentially expressed proteins using gene ontology analysis.
• Validated the expression of key proteins, such as phosphoglycerate mutase 1, using immunoblotting.

Main Results:

• Identified 136 differentially expressed proteins in S3I201-treated U87 cells.
• Observed significant alterations in biological processes including metabolism, apoptosis, cytoskeletal behavior, cell redox homeostasis, and immune response.
• Found up-regulation of apoptosis-inducing factor 1 mitochondrial and cyclophilin A, suggesting anti-tumorigenic roles.

Conclusions:

• S3I201 treatment induces significant proteomic changes in U87 glioma cells.
• The findings highlight the therapeutic potential of targeting STAT3 and cellular metabolism in GBM.
• Identified potential prognostic or predictive markers and therapeutic targets for glioblastoma treatment.